Elevated baseline triglyceride levels modulate effects of HMGCoA reductase inhibitors on plasma lipoproteins

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 6, Issue 1, 2001, Pages 47-56

  Drmanac, S ^a   Heilbron, D C ^b   Pullinger, C R ^b   Jafari, M ^c   Gietzen, D ^a   Ukrainczyk, T ^a   Cho, M H ^b   Frost, P H ^b   Siradze, K ^b   Drmanac, R T ^a   Kane, J P ^b   Malloy, M J ^b  

^a Nuvelo Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Apo E genotype; Low density lipoproteins; Very low density lipoproteins

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENOTYPE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; SEX DIFFERENCE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034758318     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840100600106     Document Type: Article

References (37)

1. Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism
2. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism
3. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation
4. Apolipoprotein E polymorphism in health and disease
5. The apolipoprotein E4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of miocardial infarction
6. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMGCoA reductase inhibitor therapy
7. Influence of apolipoprotein E phenotype on changes in plasma levels of low-density lipoprotein-cholesterol and apolipoprotein B due to the effects of simvastatin
8. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia
9. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia
10. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
11. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
12. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
13. Current and future treatment of hyperlipidemia: The role of statins
14. Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolemia treated by regular LDL apheresis
15. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease
16. A review of clinical trials comparing HMGCoA reductase inhibitors
17. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
18. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: A meta-analysis of clinical trials
19. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial)
20. Clinical outcomes in statin treatment trials: A meta-analysis
21. Review of recent clinical trials of lipid lowering in coronary artery disease
22. Treatment of primary hypercholesterolemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: A double-blind comparative study
23. Comparison of statins in hypertriglyceridemia
24. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia
25. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia
26. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum
27. Dextran sulfate-Mg2+ precipation procedure for quantitation of high-density-lipoprotein cholesterol
28. Automated simultaneous cholesterol and triglyceride determinations on the Autoanalyser II instrument: Advances in automated analysis
29. DNA sequence determination by hybridization: A strategy for efficient large-scale sequencing
30. Accurate sequencing by hybridization for DNA diagnostics and individual genomics
31. Quantitative assessment of apolipoprotein E genotypes by image analysis of PCR-RFLP fragments
32. Model selection and Akaike's information criterion (AIC): The general theory and its analytical extensions
33. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism
34. Cholesterol is required for the secretion of the very-low-density lipoprotein: In vivo studies
35. Cholesterol is required for secretion of very-low-density lipoprotein by rat liver